Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties - PubMed (original) (raw)
. 2000 Aug 4;275(31):23745-50.
doi: 10.1074/jbc.C000186200.
Affiliations
- PMID: 10837460
- DOI: 10.1074/jbc.C000186200
Free article
Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties
Y Maeshima et al. J Biol Chem. 2000.
Free article
Abstract
Vascular basement membrane is an important regulator of angiogenesis and undergoes many alterations during angiogenesis and these changes are speculated to influence neovascularization. Recently, fragments of collagen molecules have been identified to possess anti-angiogenic activity. Tumstatin (alpha3(IV)NC1 domain) is one such novel molecule with distinct anti-tumor properties and possesses an N-terminal (amino acids 54-132) anti-angiogenic and a C-terminal (amino acids 185-203) anti-tumor cell activity (Maeshima, Y., et al. 2000) J. Biol. Chem. 275, 21340-21348). Previous studies have identified the 185-203 amino acid sequence as a ligand for alpha(v)beta(3) integrin (Shahan, T. A., et al. (1999) Cancer Res. 59, 4584-4590). In the present study, we found distinct additional RGD-independent alpha(v)beta(3) integrin binding site within 54-132 amino acids of tumstatin. This site is not essential for inhibition of tumor cell proliferation but necessary for the anti-angiogenic activity. A fragment of tumstatin containing 54-132 amino acid (tum-2) binds both endothelial cells and melanoma cells but only inhibited proliferation of endothelial cells, with no effect on tumor cell proliferation. A similar experiment with fragment of tumstatin containing the 185-203 amino acid (tum-4) demonstrates that it binds both endothelial cells and melanoma cells but only inhibits the proliferation of melanoma cells. The presence of cyclic RGD peptides did not affect the alpha(v)beta(3) integrin-mediated activity of tumstatin, although significant inhibition of endothelial cell binding to vitronectin was observed. The two distinct RGD-independent binding sites on tumstatin suggest unique alpha(v)beta(3) integrin-mediated mechanisms governing the two distinct anti-tumor properties of tumstatin.
Similar articles
- Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis.
Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M, Dickerson WM, Kalluri R. Maeshima Y, et al. J Biol Chem. 2001 Aug 24;276(34):31959-68. doi: 10.1074/jbc.M103024200. Epub 2001 Jun 8. J Biol Chem. 2001. PMID: 11399763 - Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins.
Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Sudhakar A, et al. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4766-71. doi: 10.1073/pnas.0730882100. Epub 2003 Apr 7. Proc Natl Acad Sci U S A. 2003. PMID: 12682293 Free PMC article. - Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.
Hamano Y, Kalluri R. Hamano Y, et al. Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8. doi: 10.1016/j.bbrc.2005.05.130. Biochem Biophys Res Commun. 2005. PMID: 15979458 Review. - Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression.
Sudhakar A, Boosani CS. Sudhakar A, et al. Pharm Res. 2008 Dec;25(12):2731-9. doi: 10.1007/s11095-008-9634-z. Epub 2008 Jun 13. Pharm Res. 2008. PMID: 18551250 Free PMC article. Retracted. Review.
Cited by
- Preparation and Use of Decellularized Extracellular Matrix for Tissue Engineering.
McInnes AD, Moser MAJ, Chen X. McInnes AD, et al. J Funct Biomater. 2022 Nov 14;13(4):240. doi: 10.3390/jfb13040240. J Funct Biomater. 2022. PMID: 36412881 Free PMC article. Review. - Differential expression of COL4A3 and collagen in upward and downward progressing types of nasopharyngeal carcinoma.
Yang X, Wu Q, Wu F, Zhong Y. Yang X, et al. Oncol Lett. 2021 Mar;21(3):223. doi: 10.3892/ol.2021.12484. Epub 2021 Jan 21. Oncol Lett. 2021. PMID: 33613712 Free PMC article. - The matrix in cancer.
Cox TR. Cox TR. Nat Rev Cancer. 2021 Apr;21(4):217-238. doi: 10.1038/s41568-020-00329-7. Epub 2021 Feb 15. Nat Rev Cancer. 2021. PMID: 33589810 Review. - Collagen at the maternal-fetal interface in human pregnancy.
Shi JW, Lai ZZ, Yang HL, Yang SL, Wang CJ, Ao D, Ruan LY, Shen HH, Zhou WJ, Mei J, Fu Q, Li MQ. Shi JW, et al. Int J Biol Sci. 2020 May 25;16(12):2220-2234. doi: 10.7150/ijbs.45586. eCollection 2020. Int J Biol Sci. 2020. PMID: 32549767 Free PMC article. Review. - Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression.
Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Brassart-Pasco S, et al. Front Oncol. 2020 Apr 15;10:397. doi: 10.3389/fonc.2020.00397. eCollection 2020. Front Oncol. 2020. PMID: 32351878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases